Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)

Fondazione Italiana Linfomi - ETS

Status and phase: Unknown; Phase 3

Conditions: IPI≥2; Diffuse Large B-Cell Lymphoma

Treatments: Drug: Mitoxantrone; Drug: Ciclofosfamide; Drug: BCNU; Drug: VP-16; Procedure: ASCT; Drug: Vincristina; Drug: Rituximab; Drug: Lenograstim; Drug: Prednisone; Drug: Pegfilgrastim; Drug: Doxorubicina; Drug: ARA-C

Study type: Interventional

Funder types: Other

Identifiers

NCT00499018

EudraCT number 2007-000275-42

IIL-DLCL04

Details and patient eligibility

About

The purpose of this study is to define an improvement in patients randomized in four different arms:

Arm 1: R-MegaCHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 1BIS: R-CHOP14x4 + R-MAD + MAD + BEAM + ASCT; Arm 2: R-MegaCHOP14x4 + R-MegaCHOP14x2; Arm 2BIS: R-CHOP14x4 + R-CHOP14x4; Which are different in dose dense chemotherapy + Rituximab with or without intensified high dose chemoimmunotherapy and support of peripheral autologous stem cells.

Enrollment: 399 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-60;
2. Histological confirmed diagnosis of Diffuse Large B-Cell Lymphoma CD20+ (newly diagnosis or shifted from low grade NHL and not previously treated) or of Follicular Lymphoma grade III according to REAL/WHO Classification.
3. Advanced stage II, stage III and stage IV with at least two aa-IPI risk factors.
4. Age-adjusted IPI 2-3.
5. ECOG performance status 0-2.
6. LVEF>45%, measured with echocardiography.
7. Normal hepatic, renal and pulmonary functions.
8. HIV, HCV and HBV negativity.
9. HCV+ admitted only in histologically confirmed absence of replication marks.
10. Positive serology for HBV (occult carriers: AntiHBcAg+, HbsAg-, AntiHBsAg+/-) admitted only upon negativity of weakly positive HBV-DNA test.
11. Life expectancy > 3 months.
12. Negative pregnancy test.
13. Written Informed Consent.

Exclusion criteria

1. Histological diagnosis of:

   • Lymphoblastic NHL
   • Burkitt's Lymphoma
   • CD 20 negative B-cell Lymphoma
   • grade I-IIIa Follicular Lymphoma
   • Mantle Cell Lymphoma
   • Primary mediastinal NHL with exclusively intrathoracic localization.

2. Age > 60

3. Stage I disease

4. Age-adjusted IPI 0-1

5. ECOG-PS>3, if not related to Lymphoma

6. Renal impairment (creatinine>1,2 mg/dl or creatinine clearance < 60ml/min)

7. Hepatic impairment (AST/ALT or bilirubin > 2,5 times normal limit, unless due to Lymphoma)

8. HIV positive patients and/or with HBV or HCV active infection(documented by HBV-DNA and HCV-RNA positive tests)

9. Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension (resting diastolic blood pressure > 115 mmHG), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV

10. LFEV<45%

11. Severe diabetes mellitus difficult to control with adequate insulin therapy

12. Severe chronic obstructive pulmonary disease with hypoxemia

13. Active bacterial, viral of fungal infection requiring systemic therapy

14. Concurrent thrombohemolytic disease

15. HIV positivity

16. HBV positivity

17. Positive serology for HBV (occult carriers: AntiHBc+, HbsAg-, AntiHbs+/-) with positive HBV-DNA test

18. HCV positivity in presence of replication marks (HCV+, CRP+, AST 1,5-2 times normal ranges)

19. CNS localization of disease

20. Prior (during last 3 years) or concurrent malignancy except adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix or early stage prostate cancer not requiring systemic therapy, or early breast cancer treated with surgery alone. Any other co.existing medical condition that would preclude study therapy administration

21. Pregnancy or breast-feeding women

22. Inability of the patient to give her/his informed consent

23. Known hypersensitivity or anaphylactic reaction to murine antibodies or proteins

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

399 participants in 4 patient groups

1

Experimental group

Description:

R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT

Treatment:

Drug: Mitoxantrone

Drug: Prednisone

Drug: Vincristina

Drug: Doxorubicina

Drug: Lenograstim

Drug: Ciclofosfamide

Drug: Rituximab

Drug: Doxorubicina

Drug: BCNU

Drug: Vincristina

Drug: Pegfilgrastim

Drug: VP-16

Drug: ARA-C

Drug: Ciclofosfamide

Procedure: ASCT

Drug: ARA-C

1 BIS

Experimental group

Description:

R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT

Treatment:

Drug: Prednisone

Drug: Vincristina

Drug: Doxorubicina

Drug: Lenograstim

Drug: Ciclofosfamide

Drug: Rituximab

Drug: Doxorubicina

Drug: BCNU

Drug: Vincristina

Drug: Pegfilgrastim

Drug: VP-16

Drug: ARA-C

Drug: Ciclofosfamide

Procedure: ASCT

Drug: ARA-C

2

Experimental group

Description:

R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2

Treatment:

Drug: Mitoxantrone

Drug: Prednisone

Drug: Vincristina

Drug: Doxorubicina

Drug: Ciclofosfamide

Drug: Rituximab

Drug: Doxorubicina

Drug: Vincristina

Drug: Pegfilgrastim

Drug: ARA-C

Drug: Ciclofosfamide

Drug: ARA-C

2 BIS

Experimental group

Description:

R-CHOP14 x 4 Restaging + R-CHOP14 x 4

Treatment:

Drug: Prednisone

Drug: Vincristina

Drug: Doxorubicina

Drug: Ciclofosfamide

Drug: Rituximab

Drug: Doxorubicina

Drug: Vincristina

Drug: Ciclofosfamide